Sumitomo Dainippon Pharma Co., Ltd. Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 5/16/2026)
| Balance Sheet | Total Assets | 804,571,000,000.00 | ROE | 36.35 % |
| Balance Sheet | Total Equity | 292,467,000,000.00 | ROA | 13.28 % |
| Cashflow | Capital Expenditures | -4,609,000,000.00 | P/FCF | 9.42 |
| Cashflow | Free Cash Flow | 67,106,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 71,715,000,000.00 | P/CF | 8.81 |
| Income | Earnings per Share (diluted) | 268.98 | Div. Yield | 0.00 % |
| Income | Net Income | 106,865,000,000.00 | P/E | 5.91 |
| Income | Shares Outstanding | 397,299,000.00 | P/B | 2.16 |
| Income | Total Revenue | 453,294,000,000.00 | P/S | 1.39 |
Ratios calculated on: 10/14/2026
Company Description
The Sumitomo Dainippon Pharma Group sets the pharmaceutical business as its core activity but also deploys other operations covering food ingredients, food additives and chemical product materials, animal health products, diagnostics and research materials. In order to deliver innovative and useful pharmaceuticals to people worldwide as well as in Japan we make every effort in applying advanced R&D to all of our new pharmaceuticals. Aiming at improving customer satisfaction we also provide all relevant information with regard to our drug products.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.ds-pharma.co.jp
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more